Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2025-12-23 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
投资者来访接待管理制度（2025年12月）
Governance Information Classification · 95% confidence The document is titled '投资者来访接待管理制度' which translates to 'Investor Visit Reception Management System'. It outlines the company's policies and procedures for managing visits from investors and other specific stakeholders. The content includes principles for fair and equal treatment, confidentiality of non-public information, roles and responsibilities of company departments, and a commitment letter for visitors. There are no financial statements, earnings data, or regulatory filings such as annual or quarterly reports. The document is a governance-related policy document detailing internal rules and procedures for investor relations and information disclosure management. It does not announce or report financial results, nor is it a regulatory filing or announcement. Given the focus on governance practices and internal management of investor relations, the most appropriate classification is Governance Information (CGR). The document length is 3152 characters, which is relatively short but contains substantive governance content rather than a mere announcement or certification.
2025-12-23 Chinese
重大信息内部报告制度（2025年12月）
Governance Information Classification · 95% confidence The document is titled '重大信息内部报告制度' which translates to 'Major Information Internal Reporting System' and is issued by Yunnan Watson Biotechnology Co., Ltd. It outlines the internal procedures, responsibilities, and definitions related to the reporting of major information within the company. The content focuses on internal governance, reporting obligations, confidentiality, and management responsibilities regarding significant company events that could impact stock price or investment decisions. There are no financial statements, audit results, earnings data, or shareholder meeting materials. The document is a governance and compliance policy related to internal reporting and disclosure practices rather than a financial report or announcement. Therefore, it fits best under Governance Information (CGR). The document length is 5415 characters, which is sufficient for a detailed policy document, not a brief announcement or certification.
2025-12-23 Chinese
关于向银行申请并购借款并质押子公司部分股权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Yunnan Watson Biotechnology Co., Ltd. regarding the application for a merger and acquisition loan and the pledge of shares of a subsidiary as collateral. It details the board meeting resolutions, loan contract terms, pledge contract terms, and the background of the financing. The document is a formal disclosure of a financing transaction involving borrowing and share pledge, with no financial statements or earnings data presented. It is not a full financial report, earnings release, or management discussion. The content fits the category of Capital/Financing Update, as it provides updates on company fundraising and capital structure changes.
2025-12-23 Chinese
关于子公司参与国家免疫规划疫苗集中采购项目入围的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about its subsidiary's inclusion in a national vaccine procurement project. It discusses the product details, potential impact on the company, and risk factors. There is no financial data, no mention of a report being attached or published, and no regulatory certification or officer attestation. The content is an update on a business development related to procurement and sales opportunities, not a financial report or management change. It fits best as a general regulatory announcement about business activities that do not fall into other specific categories.
2025-12-23 Chinese
关于收到云南证监局行政监管措施决定书的公告
Legal Proceedings Report Classification · 95% confidence The document is an announcement from a company regarding receipt of an administrative regulatory measures decision from the local securities regulatory bureau. It details violations related to governance and disclosure of board and management remuneration, and the company's commitment to rectify the issues. There are no financial statements, earnings data, or detailed reports included. The document is a regulatory compliance announcement about legal/regulatory actions and corrective measures, fitting the category of Legal Proceedings Report (LTR). The document length is short and it is not a report publication announcement or certification letter, but a regulatory/legal update.
2025-12-19 Chinese
北京市竞天公诚律师事务所上海分所关于公司2025年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, and voting results of the 2025 first extraordinary general meeting (临时股东大会) of Yunnan Watson Biotechnology Co., Ltd. It details the legality of the meeting's call, attendance, voting procedures, and results for various resolutions, including profit distribution, appointment of auditors, and amendments to company bylaws. The document does not contain financial statements or management discussion but focuses on the legality and validity of the shareholder meeting and its resolutions. This type of document is a legal opinion related to shareholder meeting proceedings and voting results, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is about 5966 characters, which is sufficient for a detailed voting results announcement rather than a brief notice. Therefore, the appropriate classification is DVA with high confidence.
2025-12-19 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.